Mitera S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Cardiology Clinic at Mitera S.A. is dedicated to reducing the burden of heart‑related complications, with a particular focus on patients who have irregular heart rhythms.
- Prevention of stroke and systemic embolism in atrial fibrillation
- Evaluation of new oral anticoagulants for safety and efficacy
- Assessment of bleeding risk using standardized criteria
- Comparative studies to improve benefit‑risk profiles of anticoagulant therapy
Ongoing trials aim to determine whether asundexian can provide better protection against stroke while minimizing major bleeding compared with the current standard apixaban.
Neoplasms
Research in the oncology program targets aggressive cancers, seeking to extend survival and improve quality of life through novel therapeutic approaches.
- Optimization of treatment regimens for Ewing sarcoma
- Maintenance therapy strategies to increase event‑free survival
- Innovative chemotherapy combinations for acute myeloid leukemia in children and adolescents
- Evaluation of conditioning regimens for stem‑cell transplantation
- Collection of biological samples for translational research
The trials are designed to test new drug combinations and dosing strategies that could improve long‑term outcomes for patients with these high‑risk malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 5 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1GPOH gGmbH3active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mitera S.A.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 6 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.